Profluent closed a $106 million Series B led by Altimeter Capital and Bezos Expeditions to accelerate its AI‑driven protein design platform into therapeutic, agricultural and biomanufacturing applications. The financing funds expansion of discovery pipelines and commercial partnerships across multiple sectors. The round highlights sustained investor appetite for computational protein engineering that combines machine learning with biophysical modeling to design novel proteins and biologics. Profluent plans to deploy the capital into translational programs and platform engineering to shorten design cycles and increase candidate quality. The raise arrives as AI‑enabled drug discovery companies also push later‑stage programs — a signal that computational platforms are moving from toolkits toward clinic‑ready assets.